Alternatively spliced androgen receptor variants.
暂无分享,去创建一个
[1] W. Isaacs,et al. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.
[2] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[3] Majid I. Alsagabi,et al. Molecular and Cellular Pathobiology Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression , 2011 .
[4] N. Socci,et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.
[5] P. Nelson,et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.
[6] S. Payton. Prostate cancer: MDV3100 has antitumor activity in castration-resistant disease , 2010, Nature Reviews Urology.
[7] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[8] J. Céraline,et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre‐mRNA splicing variants in the 22Rv1 hormone‐refractory prostate cancer (PCa) cell line , 2010, Human mutation.
[9] H. Kung,et al. ERK Regulates Calpain 2-induced Androgen Receptor Proteolysis in CWR22 Relapsed Prostate Tumor Cell Lines* , 2009, The Journal of Biological Chemistry.
[10] H. Scher,et al. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.
[11] H. Scher,et al. Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.
[12] D. Olmos,et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.
[13] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[14] Zhiyong Guo,et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.
[15] T. McDonald,et al. Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-á-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2. , 2008, Endocrinology.
[16] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[17] D. Toft,et al. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. , 2008, Molecular endocrinology.
[18] I. Mills,et al. Structural basis for the nuclear import of the human androgen receptor , 2008, Journal of Cell Science.
[19] D. Tindall,et al. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. , 2007, Endocrine reviews.
[20] D. Tindall,et al. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. , 2007, Cancer research.
[21] C. Tepper,et al. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. , 2007, Cancer research.
[22] J. Céraline,et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. , 2007, Endocrinology.
[23] D. L. Bain,et al. Nuclear receptor structure: implications for function. , 2007, Annual review of physiology.
[24] G. Bartsch,et al. Androgen axis in prostate cancer , 2006, Journal of cellular biochemistry.
[25] N. Weigel,et al. Androgen receptor action in hormone‐dependent and recurrent prostate cancer , 2006, Journal of cellular biochemistry.
[26] D. Tindall,et al. Molecular regulation of androgen action in prostate cancer , 2006, Journal of cellular biochemistry.
[27] Kenneth J. Pienta,et al. Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.
[28] C. Sawyers,et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. , 2005, Cancer research.
[29] R. Fletterick,et al. The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.
[30] M. Menon,et al. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action , 2005, The Prostate.
[31] C. Geserick,et al. Androgen receptor function is modulated by the tissue‐specific AR45 variant , 2004, The FEBS journal.
[32] Bin He,et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.
[33] Hanne Grøn,et al. Recognition and Accommodation at the Androgen Receptor Coactivator Binding Interface , 2004, PLoS biology.
[34] Jian Hui Wu,et al. The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.
[35] F. Claessens,et al. Structural basis of androgen receptor binding to selective androgen response elements. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] C. Tepper,et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.
[37] R. Dell’eva,et al. The androgen receptor CAG repeat: a modifier of carcinogenesis? , 2002, Molecular and Cellular Endocrinology.
[38] O. Hiort,et al. The Molecular Basis of Androgen Insensitivity , 2001, Hormone Research in Paediatrics.
[39] O. Hellwinkel,et al. A unique exonic splicing mutation in the human androgen receptor gene indicates a physiologic relevance of regular androgen receptor transcript variants. , 2001, The Journal of clinical endocrinology and metabolism.
[40] Howard M. Einspahr,et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] P. Rossi,et al. Novel point mutation in the splice donor site of exon-intron junction 6 of the androgen receptor gene in a patient with partial androgen insensitivity syndrome. , 2000, The Journal of clinical endocrinology and metabolism.
[42] M. A. Carrondo,et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. , 2000, The Journal of biological chemistry.
[43] H. Gronemeyer,et al. Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain* , 1999, The Journal of Biological Chemistry.
[44] F. Claessens,et al. The Androgen Receptor Amino-Terminal Domain Plays a Key Role in p160 Coactivator-Stimulated Gene Transcription , 1999, Molecular and Cellular Biology.
[45] O. Hellwinkel,et al. Complete androgen insensitivity caused by a splice donor site mutation in intron 2 of the human androgen receptor gene resulting in an exon 2-lacking transcript with premature stop-codon and reduced expression , 1999, The Journal of Steroid Biochemistry and Molecular Biology.
[46] J. Trapman,et al. Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. , 1997, American journal of human genetics.
[47] F. Ghadessy,et al. A novel splice site mutation in the androgen receptor gene results in exon skipping and a non-functional truncated protein , 1997, Molecular and Cellular Endocrinology.
[48] W. Pratt,et al. Steroid receptor interactions with heat shock protein and immunophilin chaperones. , 1997, Endocrine reviews.
[49] N. Chamberlain,et al. Delineation of Two Distinct Type 1 Activation Functions in the Androgen Receptor Amino-terminal Domain* , 1996, The Journal of Biological Chemistry.
[50] E. Wilson,et al. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. , 1994, The Journal of biological chemistry.
[51] J. Trapman,et al. Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. , 1994, American journal of human genetics.
[52] J. Trapman,et al. Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[53] F. S. French,et al. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[55] D. Tindall,et al. Selective Role of an NH 2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion – Independent Prostate Cancer Cells , 2007 .
[56] F. Claessens,et al. Interplay between two hormone-independent activation domains in the androgen receptor. , 2006, Cancer research.
[57] M. Menon,et al. Effect of a short CAG (glutamine) repeat on human androgen receptor function , 2004, The Prostate.
[58] J. Trapman,et al. The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.